×
0 -0.014336917562724 -0.00537634408602155 -0.00537634408602155 -0.0232974910394265 -0.017921146953405 -0.0232974910394265 -0.0232974910394265
Stockreport

Conatus Pharma's IDN-7414 and Orphan Drug in Europe for PSC [Seeking Alpha]

CONATUS PHARMACEUTICALS INC (CNAT)  More Company Research Source: Seeking Alpha
Last conatus pharmaceuticals inc earnings: 8/1 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.conatuspharma.com/investor-relations
PDF Conatus Pharma's IDN-7414 and Orphan Drug in Europe for PSCThe European Medicines Agency (EMA)designates Conatus Pharmaceuticals' (NASDAQ:CNAT) IDN-7314 an Orphan Drug for the treatment of primary sclerosing cholangitis (PSC), a bile duct disease that can lead to cirrhosis and liver failure.IDN-7314 is an orally available pan-caspase protease inhibitor designed to reduce the activity of enzymes that play a key role in inflammation and cell death (apoptosis).The FDA designated the candidate an Orphan Drug for PSC in June.Now read:Biotech Analysis Central Launched: Exclusive Research From Terry Chrisomalis » [Read more]

IMPACT SNAPSHOT EVENT TIME: CNAT
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
CNAT alerts

from News Quantified
Opt-in for
CNAT alerts

from News Quantified